Apatinib as targeted therapy for sarcoma.

about

Apatinib as targeted therapy for sarcoma.

Item

http://www.wikidata.org/entity/Q54977588

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Apatinib as targeted therapy for sarcoma.

@en

Apatinib as targeted therapy for sarcoma.

@nl

type

Item

label

Apatinib as targeted therapy for sarcoma.

@en

Apatinib as targeted therapy for sarcoma.

@nl

prefLabel

Apatinib as targeted therapy for sarcoma.

@en

Apatinib as targeted therapy for sarcoma.

@nl

P1476

Apatinib as targeted therapy for sarcoma.

@en

P2093

Chao Zhang

http://www.w3.org/2001/XMLSchema#string

Feng Li

http://www.w3.org/2001/XMLSchema#string

Jilong Yang

http://www.w3.org/2001/XMLSchema#string

Jin Zhang

http://www.w3.org/2001/XMLSchema#string

Jun Zhao

http://www.w3.org/2001/XMLSchema#string

Ruwei Xing

http://www.w3.org/2001/XMLSchema#string

Sheng Teng

http://www.w3.org/2001/XMLSchema#string

Yun Yang

http://www.w3.org/2001/XMLSchema#string

Zhichao Liao

http://www.w3.org/2001/XMLSchema#string

P2860

The epidemiology of sarcoma

Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma

Critical appraisal of bevacizumab in the treatment of ovarian cancer

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.

P304

24548-24560

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.24647

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29849960

http://www.w3.org/2001/XMLSchema#string

P932

5966248

http://www.w3.org/2001/XMLSchema#string